Evidence map›Paper›PMID 40672395›Full record

ArticleFrontiers in genetics2025

Clinical validation of an integrated risk assessment test incorporating genomic and non-genomic data for sporadic breast cancer in Colombia.

Harvy Mauricio Velasco Parra, Danny Styvens Cardona, Cesar Augusto Buitrago, Melisa Naranjo Vanegas, Sebastián Gutiérrez Hincapié, Carolina Jaramillo Jaramillo, Alicia Maria Cock-Rada, Carolina Benavides Duque, Clara Patricia Piedrahita, Catalina Bustamante and 8 more

Abstract read
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Harvy Mauricio Velasco ParraPersonalized Medicine Group, Unidad de Bioentendimiento, Bioscience Center- Ayudas Diagnósticas SURA, Medellín, Colombia.
Danny Styvens CardonaPersonalized Medicine Group, Unidad de Bioentendimiento, Bioscience Center- Ayudas Diagnósticas SURA, Medellín, Colombia.
Cesar Augusto BuitragoPersonalized Medicine Group, Unidad de Bioentendimiento, Bioscience Center- Ayudas Diagnósticas SURA, Medellín, Colombia.
Melisa Naranjo Vanegas *Personalized Medicine Group, Unidad de Bioentendimiento, Bioscience Center- Ayudas Diagnósticas SURA, Medellín, Colombia.
Sebastián Gutiérrez HincapiéOmics Science Center, Unidad de Bioentendimiento, Bioscience Center - Ayudas Diagnósticas SURA, Medellín, Colombia.
Carolina Jaramillo JaramilloOmics Science Center, Unidad de Bioentendimiento, Bioscience Center - Ayudas Diagnósticas SURA, Medellín, Colombia.
Alicia Maria Cock-RadaPersonalized Medicine Group, Unidad de Bioentendimiento, Bioscience Center- Ayudas Diagnósticas SURA, Medellín, Colombia.
Carolina Benavides DuqueClinical Research Group, Bioscience Center - Ayudas Diagnósticas SURA, Medellín, Colombia.
Clara Patricia PiedrahitaMedical imaging & AI in health SURA, Bioscience Center - Ayudas Diagnósticas SURA, Medellín, Colombia.
Catalina BustamanteMedical imaging & AI in health SURA, Bioscience Center - Ayudas Diagnósticas SURA, Medellín, Colombia.
Leonel Andrés González NiñoPersonalized Medicine Group, Unidad de Bioentendimiento, Bioscience Center- Ayudas Diagnósticas SURA, Medellín, Colombia.
Jen KintleAllelica Inc., New York, United States.
Scott KulmAllelica Inc., New York, United States.
Alessandro BolliAllelica Inc., New York, United States.
Paolo Di DominicoAllelica Inc., New York, United States.
Giordano BottaAllelica Inc., New York, United States.
George B BusbyAllelica Inc., New York, United States.
Juan Pablo Valencia-ArangoPersonalized Medicine Group, Unidad de Bioentendimiento, Bioscience Center- Ayudas Diagnósticas SURA, Medellín, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast cancer risk arises from a complex interaction of genetic, environmental, and physiological factors. Integrating Polygenic Risk Scores (PRS) with clinical risk factors can enhance personalized risk prediction, especially in diverse populations like Colombia. Objective: To evaluate the predictive performance of ancestry-specific PRS combined with clinical and imaging risk factors for breast cancer in Colombian women. Methods: We developed and validated ancestry-specific PRS using diverse genetic datasets. A cohort of 1,997 Colombian women, including 510 breast cancer cases (25.5%) and 1,487 controls (74.5%), were recruited. Clinical data, such as breast density and family history, were analyzed for predictive ability using the area under the receiver operating characteristic curve (AUC). Participants were categorized into genetic ancestry groups: Admixed American, African, and European. PRS were applied to the cohort and adjusted for clinical factors to assess risk prediction. Results: Breast density and family history were the strongest individual predictors, with AUCs of 0.66 and 0.64, respectively. Most participants were of Admixed American ancestry (70% of cases, 73% of controls). The combined PRS showed an Odds Ratio per Standard Deviation of 1.56 (95% CI 1.40-1.75) and an AUC of 0.72 (95% CI 0.69-0.74) when adjusted for family history. Incorporating PRS with clinical and imaging data improved the AUC to 0.79 (95% CI 0.76-0.81), significantly enhancing predictive accuracy. Conclusion: Combining ancestry-specific PRS with clinical risk factors provides a more accurate approach for breast cancer risk stratification in Colombian women. These findings support the development of precise, population-specific risk assessment models.

Indexed as

breast cancerColombiaepidemiologypolygenic risk scorepredictionrisk stratification

Identifiers

PMID40672395
PMCPMC12263362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.